Arsalan Ahmed

Mr. Arsalan Ahmed

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Future Oncology
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
ZAZain Ul Abideen
Zain Ul Abideen
ESErum Siddiqui
Erum Siddiqui
SDShaikh Muhammad Daniyal
Shaikh Muhammad Daniyal
AAArsalan Ahmed
Arsalan Ahmed
MSMuhammad Salih
Muhammad Salih
This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies. Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence. Twenty-nine studies (n = 90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; p = 0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; p = 0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher. TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary. https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.



7 May 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
BKBilal Wazir Khan
Bilal Wazir Khan
MFMarhaba Fatima
Marhaba Fatima
RARabia Amir
Rabia Amir
RJRania Junejo
Rania Junejo
SNShayan Nawaz
Shayan Nawaz
PBPratik Bhattarai
Pratik Bhattarai
Background: Type 2 diabetes mellitus (T2DM) often progresses to require basal insulin therapy. Despite the efficacy of once-daily basal insulins such as glargine and degludec, daily injections remain a barrier to adherence. Insulin efsitora alfa, a novel once-weekly fragment crystallizable (Fc)-fusion basal insulin, may improve treatment convenience while maintaining glycemic control. Objective: To evaluate the efficacy and safety of once-weekly insulin efsitora alfa compared with once-daily basal insulin analogs in adults with T2DM. Methods: An updated systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420251118205). PubMed, Embase, and CENTRAL were searched up to 30 July 2025 for randomized controlled trials (RCTs) comparing insulin efsitora alfa with once-daily basal insulins. Pooled analyses were performed using a random-effects model in RevMan 5.4. Risk of bias was assessed with the Cochrane RoB-2 tool, and evidence certainty with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Results: Six RCTs comprising 4115 participants were included. Once-weekly insulin efsitora showed non-inferior HbA1c reduction compared with daily basal insulin (mean difference = −0.04; 95% confidence interval: –0.13 to 0.05; P = 0.35). No significant differences were observed in fasting serum glucose or body weight change. Incidents of level 1, level 2 (clinically significant), and level 3 (severe) hypoglycemia, as well as adverse and serious adverse events, were comparable between groups. Conclusion: Once-weekly insulin efsitora alfa demonstrates comparable efficacy and safety to daily basal insulin. However, further large-scale, long-term trials are warranted to confirm its durability, safety, and real-world effectiveness.

4 May 2026 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
MHMohid Haroon
Mohid Haroon
LALaiba Akram
Laiba Akram
LJLaiba Jalal
Laiba Jalal
AAArsalan Ahmed
Arsalan Ahmed
SHSaqlain Haider
Saqlain Haider

1 November 2026 in ACG Case Reports Journal
Verified
Journal Article
Open access
MUMuhammad Usman
Muhammad Usman
MSMuhammad Usman Shahbaz
Muhammad Usman Shahbaz
AAArsalan Ahmed
Arsalan Ahmed
MAMuahammad Zawar Asif
Muahammad Zawar Asif
Adnan MemonAdnan Memon
Adnan Memon
RARafif Ahmed
Rafif Ahmed
We report a fatal case of presumed primary hepatic epithelioid angiosarcoma (PHEA) in an 82-year-old woman with back pain, abdominal distension, and hyponatremia. Imaging showed ascites and hypodense hepatic lesions. Ascitic cytology was negative. Liver biopsy showed malignant cells with positive erythroblast transformation-specific regulated gene 1 (ERG) and cluster of differentiation 31 (CD31) on immunohistochemistry. Patchy synaptophysin and caudal-type homeobox 2 positivity initially suggested a neuroendocrine tumor but proved aberrant; negative chromogranin with ERG/CD31 positivity supported PHEA. She was transitioned to hospice care due to rapid clinical decline. This case highlights the atypical presentation, diagnostic pitfalls, and aggressive clinical course of PHEA.